Royalty-backed growth Nanobiotix is expanding into a capital-light, milestone and royalty-driven oncology platform around JNJ-1900, signaling opportunities for partners and suppliers aligned with milestone-based funding and royalty structures.

Radiotherapy synergy NBTXR3 aims to enhance radiotherapy at tumor sites without added healthy tissue damage and may synergize with immune checkpoint inhibitors, suggesting cross-sell opportunities with radiology, oncology clinics, and immunotherapy manufacturers.

Curadigm expansion The Curadigm Nanoprimer Platform focuses on improving drug bioavailability and systemic delivery, presenting potential collaboration or licensing avenues with broader oncology drug developers and formulation specialists.

Strong financing runway Recent equity raise and global offering extend cash runway into 2029, reducing near-term financial risk and enabling longer sales cycles for high-value collaborations, while signaling investment interest to potential partners.

Market visibility Nanobiotix’s inclusion in the Euronext Tech Leaders Index and active global investor activity enhances visibility to tech-focused biopharma funds, potential co-development investors, and strategic buyers looking for late-stage technology platforms.